Acute pulmonary effects aerosolized pentamidine study Toronto Aerosolized Pentamidine Study TAPS Group June February patients human immunodeficiency virus randomized double-blind placebo-controlled trial efficacy toxicity aerosolized pentamidine AP secondary prophylaxis Pneumocystis carinii pneumonia patient underwent spirometric evaluations treatment significant difference results baseline pulmonary function tests groups Eleven patients percent AP group cough significant reduction forced expiratory flow rates AP patients percent placebo group cough significant change expiratory flow rates bronchospastic episodes self-limited inhaled albuterol salbutamol treatment AP treatment attacks percent actual incidence bronchospasm spirometry percent mild 